Education

AbstractThe progressive number of old adults with cognitive impairment worldwide and the lack of effective pharmacologic therapies require the development of non-…

Key PointsQuestionWhat is the safety, tolerability, and efficacy of N-acetylcysteine (NAC) for patients with hereditary cystatin C amyloid angiopathy (HCCAA)?…

AbstractThe amyloid hypothesis has been a leading narrative concerning the pathophysiological foundation of Alzheimer’s and Parkinson’s disease. At the two ends of…

AbstractYears of experience watching our patients progressively decline and die from complications of Alzheimer's disease (AD) has strongly motivated us to provide…

AbstractIntroductionThis prospective observational study of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) undergoing treatment with tafamidis aims at…

BackgroundAmyloidosis is a complex and rare disease requiring specialized, multidisciplinary care to effectively manage its diverse manifestations. Existing…

AbstractVirchow described amyloidosis in 1853. Amyloidosis is the extracellular deposition of an insoluble misfolded polymerized tetramer of fibrillary protein that…

AbstractHereditary amyloid transthyretin variant (ATTRv) amyloidosis is a rare, life-threatening disease, characterized by the deposition of aggregated…

AbstractImmunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by…

AbstractIntroduction: Three treatments for Alzheimer's disease have been approved in the United States. Data are lacking on the characteristics of the initial…